Compound: Oxethazaine
SMILES: O=C(N(C(Cc1ccccc1)(C)C)C)CN(CC(=O)N(C(Cc2ccccc2)(C)C)C)CCO
InChIKey: FTLDJPRFCGDUFH-UHFFFAOYSA-N
Synonyms: Oxethazaine, 126-27-2, Oxetacaine, Oxethacaine, Oxaine, Muthesa, Strocain, Oxetacaina, oxethazine, Oxetacainum, Wy-806, WY 806, FH 099, NSC-758444, Acetamide, 2,2'-((2-hydroxyethyl)imino)bis(N-(1,1-dimethyl-2-phenylethyl)-N-methyl-, Acetamide, 2,2'-[(2-hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methyl-, IP8QT76V17, DTXSID0025818, DTXCID605818, 2-Di(N-methyl-N-phenyl-tert-butyl-carbamoylmethyl)aminoethanol, N,N-Bis(N-methyl-N-phenyl-tert-butylacetamido)-beta-hydroxyethylamine, 2,2'-((2-Hydroxyethyl)imino)bis(N-(alpha,alpha-dimethylphenethyl)-N-methylacetamide), Acetamide, 2,2'-((2-hydroxyethyl)imino)bis(N-(alpha,alpha-dimethylphenethyl)-N-methyl-, N-(1,1-dimethyl-2-phenyl-ethyl)-2-[[2-[(1,1-dimethyl-2-phenyl-ethyl)-methyl-amino]-2-oxo-ethyl]-(2-hydroxyethyl)amino]-N-methyl-acetamide, N-(1,1-dimethyl-2-phenyl-ethyl)-2-((2-((1,1-dimethyl-2-phenyl-ethyl)-methyl-amino)-2-oxo-ethyl)-(2-hydroxyethyl)amino)-N-methyl-acetamide, RefChem:857129, C05AD06, 2,2'-((2-hydroxyethyl)imino)bis(N-alpha,alpha-dimethylphenethyl)-N-methylacetamide, 2,2'-(2-Hydroxyethylimino)bis(N-(1,1-dimethyl-2-phenylethyl)-N-methylacetamide), 204-780-5, oxetacain, Mucaine, Betalgil, Oxaethacainum, Oxetacaine [INN], CHEMBL127592, 2-[2-hydroxyethyl-[2-[methyl-(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl]amino]-N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide, Oxetacaine (INN), MFCD00079202, NCGC00016382-01, CAS-126-27-2, 2,2'-((2-Hydroxyethyl)imino)bis(N-(1,1-dimethyl-2-phenylethyl)-N-methylacetamide), C28H41N3O3, Oxethacaina [Italian], Milzine, Oxetacainum [INN-Latin], Oxetacaina [INN-Spanish], 2,2'-[(2-Hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methylacetamide], CCRIS 4692, SR-05000001851, EINECS 204-780-5, Oxethazaine [USAN:JAN], BRN 2404063, UNII-IP8QT76V17, Prestwick_767, Oxethazaine (Standard), Spectrum_001657, OXETHAZAINE [MI], Prestwick0_000058, Prestwick1_000058, Prestwick2_000058, Prestwick3_000058, Spectrum2_001987, Spectrum3_001751, Spectrum4_000202, Spectrum5_001269, OXETHAZAINE [JAN], OXETHAZAINE [USAN], cid_4621, OXETACAINE [MART.], OXETACAINE [WHO-DD], Oxethazaine (JP18/USAN), SCHEMBL24489, BSPBio_000215, BSPBio_003482, KBioGR_000803, KBioSS_002137, 4-12-00-02822 (Beilstein Handbook Reference), MLS002154188, DivK1c_000715, SPECTRUM1503279, SPBio_002136, SPBio_002173, BPBio1_000237, orb1310992, Oxethazaine, analytical standard, CHEBI:31947, HMS502D17, HY-B0955R, KBio1_000715, KBio2_002137, KBio2_004705, KBio2_007273, KBio3_002702, NINDS_000715, HMS1568K17, HMS1922A04, HMS2093C15, HMS2095K17, HMS2236A03, HMS3370M13, HMS3712K17, HMS3885P21, HMS5083A13, Pharmakon1600-01503279, HY-B0955, MSK10514, Tox21_110407, BDBM50017672, CCG-39525, EBC-27170, NSC758444, AKOS024284189, Tox21_110407_1, CS-4432, DB12532, FO26625, NSC 758444, IDI1_000715, NCGC00016382-02, NCGC00016382-03, NCGC00016382-04, NCGC00016382-07, NCGC00016382-09, NCGC00095039-01, NCGC00095039-02, NCGC00095039-03, 2-[(2-hydroxyethyl)({[methyl(2-methyl-1-phenylpropan-2-yl)carbamoyl]methyl})amino]-N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide, MS-28631, SMR001233479, ST073363, SY491470, SBI-0051816.P002, DB-041818, AB00052348, NS00010381, SW196906-3, T0044, D01152, G12282, AB00052348_08, AB00052348_09, EN300-26506802, Q2412605, SR-05000001851-1, SR-05000001851-3, BRD-K56940463-001-05-4, BRD-K56940463-001-08-8, BRD-K56940463-001-13-8, BRD-K56940463-001-14-6, 2-Di(N-methyl-N-phenyl-tert-butyl-carbamoylmethyl)amino ethanol, 2-Hydroxyethyliminobis(N-[alpha,alpha-dimethylphenethyl]-N-methylacetamide), 2,2'-[(2-Hydroxyethyl)azanediyl]bis[N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide], 2,2 inverted exclamation marka-[(2-Hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methylacetamide], 2,2'-((2-HYDROXYETHYL)IMINO)BIS(N-(.ALPHA.,.ALPHA.-DIMETHYLPHENETHYL)-N-METHYLACETAMIDE), N-(1,1-Dimethyl-2-phenyl-ethyl)-2-[{[(1,1-dimethyl-2-phenyl-ethyl)-methyl-carbamoyl]-methyl}-(2-hydroxy-ethyl)-amino]-N-methyl-acetamide, N-(1,1-dimethyl-2-phenylethyl)-2-({[N-(1,1-dimethyl-2-phenylethyl)-N-methylcar bamoyl]methyl}(2-hydroxyethyl)amino)-N-methylacetamide
Theoretical properties:
molecular_formula: C28H41N3O3
molecular_weight: 467.6 g/mol
exact_mass: 467.31479218 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 12
heavy_atom_count: 34
topological_polar_surface_area: 64.1 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 219 to 220 °F (NTP, 1992)
solubility: less than 1 mg/mL at 73 °F (NTP, 1992)
Descriptions:
pubchem: Oxethazaine is an amino acid amide.
chembl: OXETHAZAINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Oxetacaine (INN, also known as oxethazaine) is a potent local anesthetic. It is administered orally (usually in combination with an antacid) for the relief of pain associated with peptic ulcer disease or esophagitis. It is also used topically in the management of hemorrhoid pain. Oral oxetacaine preparations are available in several countries, including India, South Africa, Japan, Taiwan and Brazil, but not the United States. 
Unlike most local anesthetics, oxetacaine does not break down under strongly acidic conditions. 
It is known to produce mephentermine and phentermine as metabolites.